Stephens analyst Jacob Johnson adjusted the firm’s price target on Bio-Techne to $105 from $420 following a 4-for-1 stock split that took effect this week and keeps an Overweight rating on the shares. There are no changes to his FY23 and FY24 revenue estimates for Bio-Techne, Johnson noted.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TECH:
